AWHONN Convention
 

Sessions

A5 - Compounded Versus FDA-Approved Bio-Identical Hormone Therapy: What Is the Evidence?

Title: A5 - Compounded Versus FDA-Approved Bio-Identical Hormone Therapy: What Is the Evidence?

Disciplines: Women’s Health (WH)

Learning Objectives:
  • 1. Discuss the ways in which compounded versus FDA-approved hormones are created.
  • 2. Evaluate the controversies, benefits and risks of compounded versus FDA-approved bio-identical hormone therapy.
  • 3. Compare the position statements from ACOG, North American Menopause Society, Endocrine Society, American Cancer Society, American College of Clinical Pharmacy, USPSTF, and the Global Consensus Statement on Menopausal Health regarding the use of compounded bio-identical hormone therapy.

    • Submission Description:
    When the findings of the Women’s Health Initiative were disseminated in 2002, the use of conventional hormone therapy sharply decreased. The use of compounded bio-identical hormone therapy (CBHT) increased, largely based on claims that natural CBHT is safer to use. This presentation will examine the research evidence associated with the risks and benefits of compounded versus conventional hormone therapy, so that nurses are better equipped to help clients make informed decisions about their care.
    Monday, June 13, 2016: 10:15 AM-11:45 AM
    Grapevine 1-3 (Gaylord Grapevine)
    Moderator:
    Lashea Wattie, RNC-OB, C-EFM, BSN, M.Ed
    Presenting Author:
    Marianne H. Hutti, PhD, WHNP-BC
    << Previous Session | Next Session >>